First Author: E.Coskun TURKEY
Co Author(s): P. Celemler B. Kisacik I. Erbagci U. Aksoy G. Kimyon A.M. Onat 0 0 0 0 0 0 0 0 0
Back to previous
To investigate efficacy and safety of intravitreal injection of 0.7 mg dexamethasone implant (Ozurdex) in eyes with active posterior uveitis associated with Behcet's Disease (BD)
Gaziantep University Faculty of Medicine Department of Ophthalmology
Eyes with active posterior uveitis associated with BD included the study. Demographic features of the individuals were recorded. In addition, all the individuals underwent refraction, uncorrected visual acuity (UCVA), best spectacle corrected visual acuity (BSCVA), slit-lamp biomicroscopy, and fundus examinations. Ozurdex was injected into the vitreous under local anesthesia. The control examination was performed to the patients before the injection and 1 day, 1 week, 1 month, 3 month and 6 month after the injection. Fundus fluorescence angiography (FFA) and optical coherence tomography (OCT) were performed before the injection and 1 month, 3 month and 6 month after the injection.
17 eyes of 12 patients included in the study. 6 patients were male and 6 patients were female. Mean age of the patients were 32.1±9.2 years. 15 eyes were phakic and 4 eyes were pseudophakic. FFA revealed macular edema in 5 eyes, ‘‘fern-like appearance’’ due to leakage of the retinal vasculature in 14 eyes and leakage of the optic disc in 2 eyes. UCVA and BSCVA were measured according to the decimal Snellen scale and converted to the logarithm of the minimal angle of resolution (logMAR) scale for statistical analysis. BSCVA before the injection, 1 month, 3 month and 6 month after the injection were 1,14±0,50, 0,63±0,47, 0,71±0,60 and 0,74±0,61 respectively. Intraocular pressure (IOP) before the injection, 1 month 3 month and 6 month after the injection were 14,9±3,4 mmHg, 20,2±8,4 mmHg, 14,9±5,77 mmHg and 14,5±3,2 mmHg respectively. Vitreous haze score before the injection, 1 month, 3 month and 6 month after the injection were 2,24±0,44, 1,12±0,49, 1,24±0,56 and 1,5±0,52 respectively. Central macular thickness before the injection, 1 month, 3 month and 6 month after the injection were 415±235 µm, 222±64 µm, 232±55 µm and 246±88 µm respectively.
Intraocular inflammation can be controlled effectively and safely up to 6 months with the help of intravitreal Ozurdex injection in the eyes with active posterior uveitis associated with BD